SLC5A2 and heart failure: Based on these findings, SGLT2-i received a class IA recommendation from the AHA/ACC/HFSA and ESC guidelines for the treatment of patients with heart failure with reduced ejection fraction (HFrEF)6,7 as well as for heart failure with mid-range and preserved ejection fraction (HFmrEF and HFpEF)7,6.